Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Intentional product use issue? 477 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 477 reports of Intentional product use issue have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.9% of all adverse event reports for OCRELIZUMAB.

477
Reports of Intentional product use issue with OCRELIZUMAB
0.9%
of all OCRELIZUMAB reports
12
Deaths
120
Hospitalizations

How Dangerous Is Intentional product use issue From OCRELIZUMAB?

Of the 477 reports, 12 (2.5%) resulted in death, 120 (25.2%) required hospitalization, and 9 (1.9%) were considered life-threatening.

Is Intentional product use issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 477 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Intentional product use issue?

INFLIXIMAB (11,028) RITUXIMAB (9,602) INFLIXIMAB-DYYB (7,549) TOCILIZUMAB (5,078) METHOTREXATE (4,087) PREDNISONE (3,961) ABATACEPT (3,693) ADALIMUMAB (3,557) NIVOLUMAB (3,297) LEFLUNOMIDE (3,280)

Which OCRELIZUMAB Alternatives Have Lower Intentional product use issue Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Intentional product use issue Reports All Drugs Causing Intentional product use issue OCRELIZUMAB Demographics